Intraepithelial Autoimmune Bullous Dermatoses Disease Activity Assessment and Therapy.

[1]  S. Tavakolpour,et al.  Treatment of pemphigus patients in the COVID‐19 era: A specific focus on rituximab , 2020, Dermatologic therapy.

[2]  A. Patrizi,et al.  Rituximab: a safe therapeutic option during the COVID-19 pandemic? , 2020, The Journal of dermatological treatment.

[3]  C. Korkmaz,et al.  Successful treatment of pemphigus foliaceous and ankylosing spondylitis with infliximab and methotrexate: A case report , 2020, Dermatologic therapy.

[4]  D. Murrell,et al.  Treatment considerations for patients with pemphigus during the COVID-19 pandemic , 2020, Journal of the American Academy of Dermatology.

[5]  L. Misery,et al.  Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical Trial. , 2020, JAMA dermatology.

[6]  M. Oya,et al.  Safety and efficacy of plasma exchange via direct femoral vein puncture in autoimmune blistering diseases , 2020, Journal of clinical apheresis.

[7]  Jiang Jin,et al.  Acute generalized exanthematous pustulosis induced by Mycophenolate Mofetil: A case complicated with pemphigus foliaceus , 2020, Chinese medical journal.

[8]  K. Chanprapaph,et al.  A Comparison of Azathioprine and Mycophenolate Mofetil as Adjuvant Drugs in Patients with Pemphigus: A Retrospective Cohort Study , 2019, Dermatology and Therapy.

[9]  V. A. Jones,et al.  IgA Pemphigus: A Systematic Review. , 2019, Journal of the American Academy of Dermatology.

[10]  M. Ohtsuka,et al.  Verrucous variant of pemphigus foliaceus , 2019, Clinical and experimental dermatology.

[11]  V. Werth,et al.  Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus. , 2019, JAMA dermatology.

[12]  J. Keeling,et al.  Clinical, pathologic, and immunologic features of pemphigus herpetiformis: a literature review and proposed diagnostic criteria , 2019, International journal of dermatology.

[13]  R. Ludwig,et al.  Current Clinical Trials in Pemphigus and Pemphigoid , 2019, Front. Immunol..

[14]  K. Amber,et al.  Dapsone, two birds with one stone: a response to "Dapsone advantages over trimethoprim-sulfamethoxazole for Pneumocystis pneumonia prophylaxis in immunobullous patients". , 2019, Journal of the American Academy of Dermatology.

[15]  L. Misery,et al.  Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. , 2019, The Journal of investigative dermatology.

[16]  M. Haider,et al.  Rituximab/IVIG in pemphigus – a 10-year study with a long follow-up , 2018, The Journal of dermatological treatment.

[17]  S. Grando.  Retrospective analysis of a single‐center clinical experience toward development of curative treatment of 123 pemphigus patients with a long‐term follow‐up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion‐protec , 2018, International journal of dermatology.

[18]  M. Santos,et al.  Pemphigus vegetans with isolated involvement of the nose and chest: rare variant of pemphigus vulgaris. , 2019, Anais brasileiros de dermatologia.

[19]  Li-Fang Wang,et al.  Maintenance therapy with azathioprine prolonged duration of remission for pemphigus patients who received rituximab as first-line or add-on therapy. , 2019, Journal of the Formosan Medical Association = Taiwan yi zhi.

[20]  R. Eming,et al.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status , 2018, Drugs.

[21]  D. Zillikens,et al.  Immunoadsorption of Desmoglein-3-Specific IgG Abolishes the Blister-Inducing Capacity of Pemphigus Vulgaris IgG in Neonatal Mice , 2018, Front. Immunol..

[22]  I. Bello,et al.  Pemphigus vegetans presenting as serpiginous oral, esophageal and genital mucosal ulcers undiagnosed for 3 years , 2018, Nigerian journal of clinical practice.

[23]  A. España,et al.  Rituximab Treatment Of Pemphigus Foliaceus- A Retrospective Study Of 12 Patients. , 2018, Journal of the American Academy of Dermatology.

[24]  Hayato Takahashi,et al.  Azathioprine monotherapy in autoimmune blistering diseases: A feasible option for mild to moderate cases , 2018, The Journal of dermatology.

[25]  H. Shimizu,et al.  Diagnosis and Management of Pemphigus: recommendations by an International Panel of Experts. , 2018, Journal of the American Academy of Dermatology.

[26]  Valéria Aoki,et al.  Fogo selvagem: endemic pemphigus foliaceus. , 2018, Anais brasileiros de dermatologia.

[27]  L. Chan,et al.  Unusually extensive scalp ulcerations manifested in pemphigus erythematosus. , 2018, Dermatology online journal.

[28]  S. Bornstein,et al.  Successful and well-tolerated bi-weekly immunoadsorption regimen in pemphigus vulgaris. , 2017, Atherosclerosis. Supplements.

[29]  H. Takano,et al.  Evaluating the Efficacy of Double‐Filtration Plasmapheresis in Treating Five Patients With Drug‐Resistant Pemphigus , 2017, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[30]  L. Misery,et al.  First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial , 2017, The Lancet.

[31]  D. Murrell,et al.  Validation studies of outcome measures in pemphigus , 2016, International journal of women's dermatology.

[32]  H. Trau,et al.  Efficacy of Dapsone in the Treatment of Pemphigus Vulgaris: A Single-Center Case Study , 2016, Dermatology.

[33]  A. Limper,et al.  Pneumocystis jiroveci pneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditions: a systematic review with recommendations for prophylaxis , 2016, International journal of dermatology.

[34]  M. Richard,et al.  Calculation of cut‐off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus , 2016, The British journal of dermatology.

[35]  S. Kaveri,et al.  First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up. , 2016, International immunopharmacology.

[36]  S. Kaveri,et al.  Long-Term Remissions in Recalcitrant Pemphigus Vulgaris. , 2015, The New England journal of medicine.

[37]  Yumay Chen,et al.  Pemphigus vulgaris antibodies target the mitochondrial nicotinic acetylcholine receptors that protect keratinocytes from apoptolysis. , 2015, International immunopharmacology.

[38]  N. Shear,et al.  Pemphigus herpetiformis: a case series and review of the literature , 2015, International journal of dermatology.

[39]  V. Ruocco,et al.  Pemphigus vegetans of the folds (intertriginous areas). , 2015, Clinics in dermatology.

[40]  L. Azulay-Abulafia,et al.  Dapsone in the treatment of pemphigus vulgaris: adverse effects and its importance as a corticosteroid sparing agent* , 2015, Anais brasileiros de dermatologia.

[41]  Y. Linn,et al.  Plasmapheresis in refractory pemphigus vulgaris: revisiting an old treatment modality used in synchrony with pulse cyclophosphamide. , 2015, Cutis.

[42]  R. Streilein,et al.  A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone , 2015, The British journal of dermatology.

[43]  L. Dastgheib,et al.  Assessment of the adjuvant effect of tacrolimus in the management of pemphigus vulgaris: A randomized controlled trial , 2015, The Journal of dermatological treatment.

[44]  J. Sligh,et al.  A blistering response: concurrent psoriasis and pemphigus foliaceus. , 2015, The American journal of medicine.

[45]  D. Fivenson,et al.  Two decades of using the combination of tetracycline derivatives and niacinamide as steroid-sparing agents in the management of pemphigus: defining a niche for these low toxicity agents. , 2014, Journal of the American Academy of Dermatology.

[46]  S. Jabłońska,et al.  Pemphigus herpetiformis: from first description until now. , 2014, Journal of the American Academy of Dermatology.

[47]  C. Chams‐Davatchi,et al.  Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score. , 2014, JAMA dermatology.

[48]  D. Sotiriadis,et al.  Clinical significance of anti-desmoglein-1 and -3 circulating autoantibodies in Pemphigus Patients Measured by Area Index and Intensity Score. , 2014, Acta dermato-venereologica.

[49]  T. Hashimoto,et al.  IgA pemphigus: case series with emphasis on therapeutic response. , 2014, Journal of the American Academy of Dermatology.

[50]  D. Mutasim,et al.  A Case of Pemphigus Herpetiformis Occurring in a 9‐Year‐Old Boy , 2013, Pediatric dermatology.

[51]  T. Nijsten,et al.  The development and validation of the Treatment of Autoimmune Bullous Disease Quality of Life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease , 2013, The British journal of dermatology.

[52]  A. Siadat,et al.  The efficacy of acyclovir in treatment of the pemphigus vulgaris , 2013, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[53]  N. Soter,et al.  Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients , 2013, The British journal of dermatology.

[54]  T. Nijsten,et al.  Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaire. , 2013, JAMA dermatology.

[55]  S. Khandpur,et al.  Evaluation of cyclophosphamide pulse therapy as an adjuvant to oral corticosteroid in the management of pemphigus vulgaris , 2013, Clinical and experimental dermatology.

[56]  Y. Aoyama,et al.  A higher correlation of the antibody activities against the calcium-dependent epitopes of desmoglein 3 quantified by ethylenediaminetetraacetic acid-treated enzyme-linked immunosorbent assay with clinical disease activities of pemphigus vulgaris. , 2013, Journal of dermatological science.

[57]  C. Chams‐Davatchi,et al.  Pemphigus vulgaris activity score and assessment of convergent validity. , 2013, Acta medica Iranica.

[58]  Yumay Chen,et al.  Mechanisms of Mitochondrial Damage in Keratinocytes by Pemphigus Vulgaris Antibodies* , 2013, The Journal of Biological Chemistry.

[59]  P. Deb,et al.  Pemphigus Foliaceus Masquerading as IgA Pemphigus and Responding to Dapsone , 2012, Indian journal of dermatology.

[60]  M. Trotter,et al.  Pemphigus Vegetans Associated with Intranasal Cocaine Abuse , 2012, Journal of cutaneous medicine and surgery.

[61]  S. Parameswaran,et al.  Therapeutic plasma exchange as a crisis option in severe pemphigus vulgaris. , 2012, Indian journal of dermatology, venereology and leprology.

[62]  D. Zillikens,et al.  Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients , 2012, The British journal of dermatology.

[63]  S. Greenberger,et al.  Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris. , 2012, European journal of dermatology : EJD.

[64]  R. Eming,et al.  Severity score indexes for blistering diseases. , 2012, Clinics in dermatology.

[65]  J. Roh,et al.  The Neumann Type of Pemphigus Vegetans Treated with Combination of Dapsone and Steroid , 2011, Annals of dermatology.

[66]  D. Murrell,et al.  Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome). , 2011, Dermatologic clinics.

[67]  M. Camilleri,et al.  Infection and infection prevention in patients treated with immunosuppressive medications for autoimmune bullous disorders. , 2011, Dermatologic clinics.

[68]  Pascal Joly,et al.  Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis). , 2011, Clinics in dermatology.

[69]  L. Sagi,et al.  The role of therapeutic plasma exchange in pemphigus vulgaris , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

[70]  A. Kimball,et al.  A pilot study of etanercept treatment for pemphigus vulgaris. , 2010, Archives of dermatology.

[71]  A. Kalaaji,et al.  Role of primary prophylaxis for pneumocystis pneumonia in patients treated with systemic corticosteroids or other immunosuppressive agents for immune-mediated dermatologic conditions. , 2010, Journal of the American Academy of Dermatology.

[72]  Y. Xia,et al.  A critical role of surgery in the treatment for paraneoplastic pemphigus caused by localized Castleman’s disease , 2010, Medical oncology.

[73]  S. Beissert,et al.  Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. , 2010, The Journal of investigative dermatology.

[74]  L. Bruckner-Tuderman,et al.  Recalcitrant Pemphigus Vulgaris Responding to Systemic Tacrolimus , 2010, Dermatology.

[75]  M. Black,et al.  Pulsed intravenous cyclophosphamide and methylprednisolone therapy in refractory pemphigus , 2009, The British journal of dermatology.

[76]  M. Adachi,et al.  Necrotizing fasciitis caused by Cryptococcus neoformans in a patient with pemphigus vegetans , 2009, Clinical and experimental dermatology.

[77]  H. Gürcan,et al.  Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid , 2009, The British journal of dermatology.

[78]  A. Troxel,et al.  Reliability and convergent validity of two outcome instruments for pemphigus. , 2009, The Journal of investigative dermatology.

[79]  R. A. Abdel Hay,et al.  The use of sulfasalazine and pentoxifylline (low‐cost antitumour necrosis factor drugs) as adjuvant therapy for the treatment of pemphigus vulgaris: a comparative study , 2009, The British journal of dermatology.

[80]  H. Mouquet,et al.  ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. , 2009, Archives of dermatology.

[81]  S. Misbah,et al.  An ‘n‐of‐1’ placebo‐controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris , 2009, The British journal of dermatology.

[82]  H. Shimizu,et al.  A randomized double-blind trial of intravenous immunoglobulin for pemphigus. , 2009, Journal of the American Academy of Dermatology.

[83]  V. Sehgal,et al.  Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome , 2009, International journal of dermatology.

[84]  D. Murrell,et al.  Interventions for pemphigus vulgaris and pemphigus foliaceus. , 2009, The Cochrane database of systematic reviews.

[85]  H. Gürcan,et al.  Efficacy of Dapsone in the Treatment of Pemphigus and Pemphigoid , 2009, American journal of clinical dermatology.

[86]  Z. Miltényi,et al.  Successful Immunomodulatory Therapy in Castleman Disease with Paraneoplastic Pemphigus Vulgaris , 2009, Pathology & Oncology Research.

[87]  E. Kurtz,et al.  Treatment of refractory pemphigus erythematosus with rituximab , 2008, International journal of dermatology.

[88]  Y. Aoyama,et al.  Severe pemphigus vulgaris: successful combination therapy of plasmapheresis followed by intravenous high-dose immunoglobulin to prevent rebound increase in pathogenic IgG. , 2008, European journal of dermatology : EJD.

[89]  C. Günther,et al.  Successful therapy of pemphigus vulgaris with immunoadsorption using the TheraSorb™ adsorber , 2008, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[90]  H. Shimizu,et al.  Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. , 2008, Journal of the American Academy of Dermatology.

[91]  E. Berti,et al.  Rationale and efficacy for the use of rituximab in paraneoplastic pemphigus , 2008, Expert review of clinical immunology.

[92]  G. Russo,et al.  Adjuvant High-Dose Intravenous Immunoglobulin Therapy Can Be Easily and Safely Introduced as an Alternative Treatment in Patients with Severe Pemphigus Vulgaris , 2008, American journal of clinical dermatology.

[93]  D. Fivenson,et al.  Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. , 2008, Archives of dermatology.

[94]  T. Koussidou,et al.  An alternate‐day corticosteroid regimen for pemphigus vulgaris. A 13‐year prospective study , 2007, Journal of the European Academy of Dermatology and Venereology : JEADV.

[95]  C. Chams‐Davatchi,et al.  Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. , 2007, Journal of the American Academy of Dermatology.

[96]  D. Zillikens,et al.  Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases , 2007, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[97]  Bingxin Zhang,et al.  Paraneoplastic pemphigus , 2007, The Journal of dermatology.

[98]  A. Nanda,et al.  Paraneoplastic pemphigus in association with B‐cell lymphocytic leukemia and hepatitis C: favorable response to intravenous immunoglobulins and prednisolone , 2007, International journal of dermatology.

[99]  T. Hashimoto,et al.  A novel case of IgA paraneoplastic pemphigus associated with chronic lymphocytic leukemia. , 2007, Journal of the American Academy of Dermatology.

[100]  M. Olszewska,et al.  Efficacy and Safety of Cyclophosphamide, Azathioprine, and Cyclosporine (Ciclosporin) as Adjuvant Drugs in Pemphigus Vulgaris , 2007, American journal of clinical dermatology.

[101]  R. Eming,et al.  Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. , 2007, European journal of dermatology : EJD.

[102]  G. Annessi,et al.  Pemphigus foliaceus treated with etanercept. , 2006, Journal of the American Academy of Dermatology.

[103]  E. Bröcker,et al.  Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption , 2006, Clinical and experimental dermatology.

[104]  L. Cavacini,et al.  Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. , 2006, The New England journal of medicine.

[105]  H. Gollnick,et al.  A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. , 2006, Archives of dermatology.

[106]  S. Tan,et al.  Comparison of desmoglein ELISA and indirect immunofluorescence using two substrates (monkey oesophagus and normal human skin) in the diagnosis of pemphigus , 2005, The Australasian journal of dermatology.

[107]  V. Werth,et al.  Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. , 2005, Archives of dermatology.

[108]  E. Bröcker,et al.  Intravenous dexamethasone‐cyclophosphamide pulse therapy in comparison with oral methylprednisolone‐azathioprine therapy in patients with pemphigus: Results of a multicenter prospectively randomized study , 2005, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[109]  F. d'Amore,et al.  Alemtuzumab‐induced remission of both severe paraneoplastic pemphigus and leukaemic bone marrow infiltration in a case of treatment‐resistant B‐cell chronic lymphocytic leukaemia , 2004, European journal of haematology.

[110]  M. Pittelkow,et al.  Pemphigus vulgaris acantholysis ameliorated by cholinergic agonists. , 2004, Archives of dermatology.

[111]  G. Anhalt.  Paraneoplastic pemphigus. , 2004, The journal of investigative dermatology. Symposium proceedings.

[112]  Guizhi Zhou,et al.  Mild pemphigus foliaceus responding to combination therapy with niacinamide and tetracycline , 2003, International journal of dermatology.

[113]  D. Mimouni,et al.  Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus. , 2003, Journal of the American Academy of Dermatology.

[114]  L. Gergely,et al.  Successful Treatment of B Cell Chronic Lymphocytic Leukemia-Associated Severe Paraneoplastic Pemphigus with Cyclosporin A , 2003, Acta Haematologica.

[115]  L. Borradori,et al.  Topical tacrolimus (FK506) for relapsing erosive stomatitis in paraneoplastic pemphigus , 2003, The British journal of dermatology.

[116]  B. Orazi,et al.  Plasmapheresis therapy in pemphigus vulgaris and bullous pemphigoid. , 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[117]  J. Roujeau,et al.  [Treatment of pemphigus vulgaris by azathioprine and low doses of prednisone (Lever scheme)]. , 2003, Annales de dermatologie et de venereologie.

[118]  E. Ruocco,et al.  Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. , 2002, Archives of dermatology.

[119]  T. Nishikawa,et al.  Monitoring disease activity in pemphigus with enzyme‐linked immunosorbent assay using recombinant desmogleins 1 and 3 , 2002, The British journal of dermatology.

[120]  A. Kanwar,et al.  Long-Term Efficacy of Dexamethasone-Cyclophosphamide Pulse Therapy in Pemphigus , 2002, Dermatology.

[121]  A. Ahmed,et al.  Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus. , 2002, European journal of dermatology : EJD.

[122]  A. Ahmed,et al.  Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy. , 2002, Journal of the American Academy of Dermatology.

[123]  A. Ahmed,et al.  Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. , 2001, Journal of the American Academy of Dermatology.

[124]  E. Billingsley,et al.  Use of mycophenolate mofetil in the treatment of paraneoplastic pemphigus , 2000, The British journal of dermatology.

[125]  M. Hertzberg,et al.  Paraneoplastic pemphigus in two patients with B‐cell non‐Hodgkin's lymphoma: Significant responses to cyclophosphamide and prednisolone , 2000, American journal of hematology.

[126]  J. Bystryn,et al.  Methotrexate as an adjuvant treatment for pemphigus vulgaris. , 1999, Archives of dermatology.

[127]  M. Grever,et al.  Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease. , 1999, Journal of the American Academy of Dermatology.

[128]  A. Calebotta,et al.  Pemphigus vulgaris: benefits of tetracycline as adjuvant therapy in a series of thirteen patients , 1999, International journal of dermatology.

[129]  E. Bröcker,et al.  Paraneoplastic pemphigus treated with dexamethasone/ cyclophosphamide pulse therapy. , 1999, European journal of dermatology : EJD.

[130]  J. Nakano,et al.  Pemphigus Vegetans Involving the Esophagus , 1998, The Journal of dermatology.

[131]  T. Nishikawa,et al.  Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. , 1997, Journal of immunology.

[132]  V. Kesic,et al.  Retroperitoneal round‐cell liposarcoma associated with paraneoplastic pemphigus presenting as lichen planus pemphigoides‐like eruption , 1997, International journal of dermatology.

[133]  A. Ahmed,et al.  Long-term remission in selected patients with pemphigus vulgaris treated with cyclosporine. , 1997, Journal of the American Academy of Dermatology.

[134]  F. Wojnarowska,et al.  Minocycline is a useful adjuvant therapy for pemphigus , 1996 .

[135]  N. Korman,et al.  Paraneoplastic pemphigus: potential therapeutic effect of plasmapheresis , 1996, The British journal of dermatology.

[136]  K. Søndergaard,et al.  The steroid-sparing effect of long-term plasmapheresis in pemphigus. , 1995, Acta dermato-venereologica.

[137]  D. Ioannides,et al.  TREATMENT OF ORAL PEMPHIGUS VULGARIS , 1994, International journal of dermatology.

[138]  M. Pittelkow,et al.  Paraneoplastic pemphigus: a case of prolonged survival. , 1994, Mayo Clinic proceedings.

[139]  M. Lapidoth,et al.  The efficacy of combined treatment with prednisone and cyclosporine in patients with pemphigus: preliminary study. , 1994, Journal of the American Academy of Dermatology.

[140]  A. Luisi,et al.  Cyclosporine for the treatment of pemphigus vulgaris. , 1994, The Annals of pharmacotherapy.

[141]  R. Wolf,et al.  Drug-induced pemphigus. I. A survey. , 1993, Clinics in dermatology.

[142]  D. Fivenson,et al.  Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. , 1993, Journal of the American Academy of Dermatology.

[143]  Y. C. Liu,et al.  Paraneoplastic pemphigus: a report of three cases including one long-term survivor. , 1992, Journal of the American Academy of Dermatology.

[144]  T. Lotti,et al.  The Role of Cyclosporine A in the Treatment of Pemphigus Erythematosus , 1991, International journal of dermatology.

[145]  K. V. Ratnam,et al.  Pemphigus Therapy with Oral Prednisolone Regimens A 5‐Year Study , 1990, International journal of dermatology.

[146]  V. Ruocco,et al.  Drug-induced pemphigus. , 1998, Clinics in dermatology.

[147]  B. McConkey,et al.  Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. , 1986, British medical journal.

[148]  J. Bystryn.  Adjuvant therapy of pemphigus. , 1984, Archives of dermatology.

[149]  A. Ahmed,et al.  Pemphigus erythematosus: Presentation of four cases and review of literature , 1984 .

[150]  A. Ahmed,et al.  Pemphigus vegetans. Neumann type and Hallopeau type. , 1984, International journal of dermatology.

[151]  J. Roujeau,et al.  Plasma exchange in corticosteroid‐resistant pemphigus , 1982, The British journal of dermatology.

[152]  W. F. Lever,et al.  Treatment of pemphigus vulgaris with methotrexate. , 1969, Archives of dermatology.